Literature DB >> 23902447

Evaluation of racing performance after colic surgery in Thoroughbreds: 85 cases (1996-2010).

Joy E Tomlinson1, Raymond C Boston, Thomas Brauer.   

Abstract

OBJECTIVE: To determine racing performance after surgery for colic in Thoroughbreds.
DESIGN: Retrospective cohort study. ANIMALS: 85 racing Thoroughbreds that survived to discharge following colic surgery and 170 race-matched reference horses. PROCEDURES: Earnings, starts, and earnings per start were compared between horses that underwent surgery and reference horses, the proportions of horses that returned to racing were analyzed, and career longevity was determined.
RESULTS: Among 85 racing Thoroughbreds that underwent colic surgery, 31 (36%) had primarily small intestinal lesions, of which 11 underwent resection; 54 (64%) had large intestinal lesions, of which 2 underwent resection. Fifty-nine of 85 (69%) horses that underwent colic surgery returned to racing after a 6-month recovery period versus 125 of 170 (73%) reference horses (OR, 0.81). In the 36-month postoperative period, reference horses earned a mean of $7,866 more, had a mean of 0.26 more starts, and had mean earnings per start of $29 more than horses that underwent surgery. Horses that underwent surgery did not have different career lengths than reference horses. CONCLUSIONS AND CLINICAL RELEVANCE: Horses that underwent colic surgery did not have a significant reduction in measures of performance or career length, compared with a reference cohort.

Entities:  

Mesh:

Year:  2013        PMID: 23902447     DOI: 10.2460/javma.243.4.532

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  1 in total

1.  Long-term follow-up on recovery, return to use and sporting activity: a retrospective study of 236 operated colic horses in Finland (2006-2012).

Authors:  Isa Anna Maria Immonen; Ninja Karikoski; Anna Mykkänen; Tytti Niemelä; Jouni Junnila; Riitta-Mari Tulamo
Journal:  Acta Vet Scand       Date:  2017-01-05       Impact factor: 1.695

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.